Effects of Recombinant Human Bone Morphogenetic Protein-2 Dose and Ceramic Composition on New Bone Formation and Space Maintenance in a Canine Mandibular Ridge Saddle Defect Model.

Treatment of mandibular bone defect is a significant clinical challenge. Maintenance of the height and width of the ridge of the mandible are important to dental implant placement and restoration of a normal tooth. While guided bone regeneration using a protective membrane is an effective strategy to maintain the anatomical contours of the ridge and promotes the formation of new bone, complications have been reported, including a failure Zebra Recombinant Proteins of the wound, seroma, and exposure of corruption that leads to infection.

 In this study, we investigated injecting low viscosity (LV) polyurethane / ceramic composites coupled with 100 mg / mL (low) or 400 mg / mL (high) bone recombinant human morphogenetic protein-2 (rhBMP-2) as a space-maintaining graft The lower jaw bone ridge saddle Model handicapped dogs. LV grafts injected as a reactive paste set within 5-10 minutes to form a porous composite solid with bulk modulus exceeding 1 MPa. 

We hypothesize that the compression-resistant graft LV will increase new bone formation and maintain the anatomical contours of the ridge of the mandible without the use of protective membranes. In the rhBMP-2 recommended dose for collagen carrier of sponge absorbed in dogs (400 mg / mL), graft LV maintained the width and height of the host ridge of the mandible and supported the formation of new bone, while at suboptimal (100 ug / mL) dose, contour anatomy of the ridge is not retained. 

These findings indicate that bone graft compression resistant to the bulk modulus exceeding 1 MPa and rhBMP-2 dose comparable to that recommended for operator support new bone formation and maintaining high collagen sponge ridge and ridge width of mandibular defects with no protective membrane

Evaluation of two recombinant Leishmania proteins identified by immunoproteomic approach as a tool for serodiagnosis of canine visceral and human tegumentary leishmaniasis.

serological diagnostic test for canine and human leishmaniasis these problems associated with the sensitivity and / or specificity them. More recently, an approach immunoproteomic do with the protein antigens identified parasite Leishmania infantum new.

 In this study, the diagnostic properties of these two proteins, cytochrome c oxidase and IgE-dependent histamine-releasing factor, was evaluated for serodiagnosis of canine visceral (CVL) and human tegumentary (HTL) leishmaniasis. Simian Recombinant Proteins For the diagnosis of CVL, serum samples from the infected dogs are not living in areas endemic or non-endemic leishmaniasis, sera of asymptomatic or symptomatic visceral leishmaniasis (VL) dogs, of Leish-Tec (®) -vaccinated dogs, and sera from animals experiment infected by Trypanosoma cruzi or Ehrlichia canis used.

 For the diagnosis of HTL, sera from non-infected subjects in endemic areas of leishmaniasis, sera from patients with active leishmaniasis skin or mucosa, as well as those of patients infected with T. cruzi employed.